Overview Full Year Research & Development Revenue of $19.7 Million; Q4 2025 Revenue of $3.8 MillionCash Rose to $15.4 Million at December 31, 2025 DALLAS, March 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (“AI”) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the fourth quarter (“Q4 2025”) and full year (“FY 2025”) ended December 31, 2025 ...

Group 1 - Spectral AI stock has seen significant gains, attributed to recent funding developments and positive investor sentiment [1][3] - The company received immediate, non-dilutive funding from BARDA, adding to the previously committed $54.9 million under an existing contract, which has a total potential value of up to $150 million [2] - Spectral AI will contribute an additional $9.7 million towards the development costs associated with advancements in their technology [2] Group 2 - The funding will support the development of the DeepView System, which is aimed at enhancing FDA clearance efforts and expediting Phase II initiatives, including total body surface area mapping [4] - DeepView is designed for use in emergency departments, trauma centers, and burn centers, facilitating faster, data-driven clinical treatment decisions in wound care [5] - As of Thursday morning, Spectral AI shares increased by 8.33%, reaching a price of $1.30 [7]

DALLAS, March 18, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received $31.7 million in funding from the Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate and support additional feature aspects for the Company’s DeepView® System, its AI-driven burn wound imaging technolog ...

DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 on Tuesday, March 24, 2026 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time that day t ...

Core Viewpoint - Spectral AI, Inc. has appointed Vincent S. Capone as Chief Executive Officer, effective February 9, 2026, as the company moves towards the commercialization of its AI-driven burn wound assessment device, the DeepView System [1][2]. Company Leadership - Vincent S. Capone, previously the Chief Financial Officer and General Counsel, is recognized for his leadership skills and vision for the company's future, having played a crucial role in its development [3]. - Dr. J. Michael DiMaio, Chairman of the Board, expressed confidence in Capone's ability to guide the company strategically as it evolves [3]. Product Development - The DeepView System is a proprietary, non-invasive device aimed at providing clinicians with an objective assessment of burn wounds, marking a significant advancement in wound care [2][5]. - The FDA submission for the DeepView System occurred in June 2025, representing a major milestone for the company [4]. Company Mission - Spectral AI aims to revolutionize wound care management by offering fast and accurate treatment insights, ultimately improving patient outcomes and reducing healthcare costs [5]. - The company has been recognized in TIME's list of World’s Top HealthTech companies for 2025, highlighting its innovative approach in the healthcare sector [5].

Financial Data and Key Metrics Changes - Research and development revenue decreased to $3.8 million in Q3 2025 from $8.2 million in Q3 2024, reflecting reduced reimbursements under the BARDA Project Bioshield contract [9] - Gross margin decreased to 42.7% from 44.8% year-over-year due to a lower percentage of direct labor as a part of total reimbursed costs [10] - Net loss for Q3 2025 was $3.6 million, compared to a net loss of $1.5 million in Q3 2024, attributed to reduced revenue and higher administrative expenses [10] - Cash and cash equivalents totaled $10.5 million as of September 30, 2025, up from $5.2 million at the end of 2024, with a consistent cash balance since June 30, 2025 [11][12] - Revenue guidance for 2025 was reduced from $21.5 million to $18.5 million due to anticipated reduced work on the BARDA contract and timing effects from the U.S. government shutdown [12] Business Line Data and Key Metrics Changes - The company continues to focus on the DeepView System, with plans for a U.S. launch next year, supported by a recent registered direct offering that added $7.6 million to cash reserves [5][12] - The company is working on a commercialization strategy for the DeepView System, which includes broad applications beyond burns [8] Market Data and Key Metrics Changes - The company has received positive feedback from international markets where units have been placed, indicating ease of use and effectiveness in treating burn patients [22] - Discussions are ongoing to expand into the U.K. and parts of Europe, with plans to upgrade the current device based on U.S. market learnings [42][43] Company Strategy and Development Direction - The company is focused on three principles: finance, focus, and finish, as it prepares for the commercialization of the DeepView System [4] - The company aims to leverage its existing relationships within the burn community to facilitate initial sales post-FDA clearance [40] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the FDA submission process, indicating no anticipated delays despite the government shutdown [17] - The company expects 2026 to be a transitional year with relatively flat revenue compared to 2025, with significant growth anticipated in 2027 and 2028 [20] Other Important Information - The company is actively communicating with the FDA regarding its submission, with positive interactions noted, particularly concerning the statistical analysis plan [27] - The handheld module for military use is under development, with positive feedback received on its preliminary design [30] Q&A Session Summary Question: Impact of government shutdown on FDA submission - Management confirmed that the FDA submission is on track for approval in the first half of 2026, with delays primarily affecting discussions with BARDA [17][18] Question: Revenue expectations for 2026 - Management indicated that 2026 may see a slight reduction in revenue compared to 2025, but overall expectations remain stable [20] Question: Feedback from international units - Positive feedback has been received from international sites, informing preparations for the U.S. launch [22] Question: Progress with FDA communications - Management reported good communication with the FDA, with ongoing discussions about additional testing and adjustments [27] Question: Status of the handheld module development - Development is progressing well, with military testing ongoing and plans for civilian applications [30] Question: Commercialization preparations - The company is hiring additional personnel for commercialization efforts and leveraging existing relationships in the burn community [40]

Core Viewpoint - Spectral AI Inc. is raising $7.6 million to enhance its balance sheet and support the development of its DeepView System, aiming for commercial readiness by 2026 [1][2][3]. Group 1: Capital Raise Details - The company plans to issue 4 million shares of common stock at a price of $1.90 per share, along with corresponding warrants priced at $2.51 per share [2]. - The capital raised will facilitate the expansion of clinical indications for the DeepView System [2][3]. Group 2: Company Overview - Spectral AI Inc. specializes in medical diagnostics using AI and multispectral imaging to evaluate wound healing potential [4]. - The technology developed by the company aids clinicians in making quicker and more accurate treatment decisions for patients suffering from burns and diabetic foot ulcers [4]. Group 3: Strategic Commitment - The company remains committed to its current BARDA Project BioShield (PBS) contract while advancing its AI technology to enhance product offerings [3].

Core Insights - The article discusses the 13 best AI stocks to buy under $20, highlighting the significant role of artificial intelligence in investment strategies over the past two years, contributing to record highs in the equity market [1] - Concerns about an AI bubble are rising, with experts suggesting the need for diversification into stocks trading at discounted valuations [3][4] - A Bank of America survey indicates that a third of fund managers view the AI bubble as a major risk, yet this has not significantly dampened overall positive market sentiment [4][5] Industry Overview - The AI sector has been a driving force behind the recent equity market rally, with major tech companies significantly influencing the S&P 500 index [1] - The AI boom has led to historical highs in stock valuations, prompting investors to reconsider their strategies [2] - The concept of a "rational bubble" has been introduced, suggesting that while there are opportunities, only a few companies will emerge as winners [3] Company Insights - **Veritone Inc. (NASDAQ:VERI)**: - Current share price is $6.14, with a 180% increase over the past six months [9] - Analysts at Needham initiated coverage with a 'Buy' rating and a $10 price target, expecting continued outperformance driven by growth in its aiWARE platform and other market opportunities [10][11][12] - **Spectral AI Inc. (NASDAQ:MDAI)**: - Current share price is $2.22, with 7 hedge fund holders [13] - The company announced a $7.6 million offering to support the expansion of its DeepView System, which is aimed at enhancing clinical indications and preparing for commercial readiness in 2026 [13][14][15] - Spectral AI utilizes AI and multispectral imaging for medical diagnostics, particularly in assessing wound healing potential [16]

Core Viewpoint - Spectral AI, Inc. has announced a $7.6 million offering to support the growth and development of its DeepView System, aimed at enhancing medical diagnostics in wound care [1][3]. Financing Details - The offering consists of 4,000,000 shares of common stock and pre-funded warrants priced at $1.90 per share, with corresponding warrants having an exercise price of $2.51 per share [2]. Company Strategy and Development - The Chairman of the Board expressed satisfaction in securing institutional funding, which will facilitate the continued development of the DeepView System and prepare it for commercial readiness in 2026 [3]. - The company remains committed to its BARDA Project BioShield contract while advancing its AI technology to expand product offerings [3]. About the DeepView System - The DeepView System is designed to provide clinicians with an objective assessment of a burn wound's healing potential, aiming to improve patient outcomes and reduce healthcare costs [5]. - The system utilizes algorithm-driven results to exceed current standards of care in wound management [5].

Core Insights - Spectral AI, Inc. has been recognized in TIME's World's Top HealthTech Companies 2025 list, highlighting its innovative contributions to medical diagnostics in wound care [1][2][3] Company Overview - Spectral AI is a Dallas-based predictive AI company focused on enhancing medical diagnostics for wound care, particularly for burn patients [3] - The company is developing the DeepView System, which aims to provide clinicians with an objective assessment of a burn wound's healing potential before treatment [3] - The DeepView System is designed to improve patient outcomes and reduce healthcare costs by offering fast and accurate treatment insights [3] Recognition and Impact - The TIME list, compiled with Statista Inc., evaluated thousands of HealthTech companies, recognizing 400 for their financial performance, reputation, and online engagement [2] - J. Michael DiMaio, M.D., Chairman of Spectral AI, emphasized that this recognition is a significant milestone for the company and its technology [3]